Unknown NA INTERVENTIONAL 2-arm NCT04049149

Precision Medicine in Chinese Patients With Young Onset Diabetes

Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) in Chinese Patients With Young Onset Diabetes

Sponsor: Chinese University of Hong Kong

Conditions Type 2 Diabetes

Interventions Biogenetic explanation and endocrinologist intensive managment Usual care management

Updated 8 times since 2019 Last updated: Jul 19, 2022 Started: Jan 14, 2020 Primary completion: Dec 31, 2024 Completion: Dec 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Type 2 Diabetes, this trial is ongoing. The trial is conducted by Chinese University of Hong Kong and has accumulated 8 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Unknown NA
Feb 2025 — Sep 2025 [monthly]

Unknown NA

Status: Active Not Recruiting → Unknown
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting NA
Sep 2022 — Jul 2024 [monthly]

Active Not Recruiting NA

Status: Recruiting → Active Not Recruiting

▶ Show 3 earlier versions

Jan 2021 — Sep 2022 [monthly]

Recruiting NA
Feb 2020 — Jan 2021 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Sep 2019 — Feb 2020 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese University of Hong Kong

Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shatin, Hong Kong